Mucormycosis is a relatively unusual opportunistic infection, which presents an aggressive disorder with high rate of mortality (more than 60% in untreated conditions) and significant morbidity (
2). Mucorales especially
Rhizopusarrhizus, a subclass of zygomycetes species, are the principle etiological agents of this life-threatening infection (
1). A growing body of evidence has indicated that phagocytes mononuclear and polymorphonuclear play a cardinal role in killing mucorales via production of oxidative metabolites and the cationic peptides defensins (
1). Therefore, hyperglycemia, acidosis, neutropenia, hematologic disorders and steroid use which have been shown to impair these defensive mechanisms, predispose patients to mucormycosis infection (preferentially the rhinocerebral form) and exacerbate its dissemination (
1). This hypothesis is supported by the fact that mucormycosis is not a common opportunistic infection in human immunodeficiency virus (HIV) infected patients, who have relatively preserved neutrophil count and function (
3). Several clinical syndromes including pulmonary, cutaneous, gastrointestinal, rhinocerebral and disseminated mucormycosis have been described (
1). Rhino-orbito-cerebral mucormycosis accounts for about 30-50% of all cases and appears to be the most common form of disease and develops in a setting of diabetic ketoacidosis in more than 60% of patients (
1). Inhaled fungal elements in a susceptible patient sequester in paranasal sinuses, usually ethmoid, leading to invasion to sinuses, orbit and the brain. Fever, headaches and ophthalmoplegia are the main clinical manifestations which are followed by blindness, frozen eyes, cavernous sinus thrombosis, large arteries vasculopathy and stroke (
4). Early diagnosis is mandatory for managing of this life-threatening disorder (
5). In a retrospective study, based on analyzing clinical course and outcome of 30 cases of mucormycosis in educational hospitals of Tehran, Barati et al. showed that there is a strong correlation between delay in diagnosis and mortality. They reported that timely amphotricin administration and surgical intervention were successful in preventing disease progression to critical structures and reducing mortality rate (
6). Of note, according to reported autopsies, definite diagnosis in more than half of the patients was confirmed by a postmortem pathological assay (
1). Thus it appears that despite a negative primary biopsy, if there is a strong clinical suggestion, the treatment should be continued until confirmation of a reasonable alternative diagnosis. Headaches, ophthalmoplegia and blurred vision could be a warning sign of progressive rhinocerebral mucormycosis; thus in very diabetic patients with the above findings, urgent evaluation with brain and paranasal sinus imaging, preferentially MRI and diagnostic nasal endoscopic approach should be considered (
4). Once the disease is clinically suspected, antifungal treatment with polyene agents, amphotericin B deoxycholate and its lipid derivatives, should be started as soon as possible (
1,
2). At the beginning of the disease, mucosal tissues may appear pink and mistakenly be evaluated as normal. Thus, if clinical suspicion index is high, blind mucosal biopsies must be taken (
1). Modifying of predisposing factors including hyperglycemia, ketoacidosis, anemia, and discontinuation of deferoxamine and steroids is mandatory in management and are strongly recommended (
4). Even, if the fungal agent is susceptible to antifungal drugs in vitro, urgent surgical debridement is necessary for reducing the chance of angioinvasion and CNS complication (
4). Necrosis and thrombosis reduce drug penetration ton the site of infection (
1). Some azole derivatives such as posaconazole and ravuconazole have promising in vitro inhibitory effects on mucorales growth, which has been supported by several in vivo reports (
4,
7). Nonetheless, these agents should only be used for adjunctive therapy in combination with amphotericin (
1,
4). In contrast todeferoxamine which is a precipitating factor for mucormycosis, new iron chelating agents such as deferasirox have been elucidated that not only do not exacerbate Rhizopus infection, but also have in vitro fungicidal activity and improve survival of patients with mucormycosis especially when used in combination with amphotericin (
4). Recently, hyperbaric oxygen and granulocyte-macrophage colony-stimulating factor have been shown to exhibit beneficial therapeutic effects in adjunct with standard treatment (antifungal amphotericin plus surgical debridement) (
1,
4). Mucormycosis is a rare infectious disease with irrecoverable neurological complications. Unfortunately, despite its characteristic course, this life-threatening disorder is usually associated with high mortality and morbidity mainly because of delay in diagnosis in primary care centers. Hence, high index of clinical suspicion is necessary for preventing devastating sequels. Urgent surgical debridement associated with antifungal agents (amphotericin with posaconazole) is the mainstay of treatment.